Efficacy of canagliflozin (CANA) in combination with metformin (MET) in patients with T2DM: Results from 3 studies

被引：0

作者：

Qiu, Rong ^{[1
]}

Xie, John ^{[1
]}

Hamilton, Gill ^{[2
]}

Canovatchel, William ^{[1
]}

Fegade, Mayuresh ^{[3
]}

机构：

[1] Janssen Res & Dev LLC, Raritan, NJ USA

[2] Janssen Cilag Ltd, High Wycombe, Bucks, England

[3] Janssen Med Affairs, Bombay, Maharashtra, India

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2016年 / 120卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PD-83

引用

页码：S118 / S118

页数：1

共 50 条

[1] Combination Therapy of Canagliflozin and Teneligliptin in Japanese Patients with T2DM: Results from Phase 3 Studies
Kaku, Kohei
Kadowaki, Takashi
Inagaki, Nobuya
Kondo, Kazuoki
Nishimura, Kenichi
Kaneko, Genki
Maruyama, Nobuko
Nakanishi, Nobuhiro
Iijima, Hiroaki
Watanabe, Yumi
Goda, Maki
[J]. DIABETES, 2017, 66 : A319 - A319
[2] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks
Forst, Thomas
Guthrie, Robert
Goldenberg, Ronald
Yee, Jacqueline
Vijapurkar, Ujjwala
Meininger, Gary
Stein, Peter
[J]. DIABETES, 2013, 62 : A284 - A284
[3] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
Lavalle Gonzalez, Fernando J.
Januszewicz, Andrzej
Davidson, Jaime
Qiu, Rose
Tong, Cindy
Meininger, Gary
[J]. DIABETES, 2013, 62 : A61 - A61
[4] Canagliflozin review - safety and efficacy profile in patients with T2DM
Jakher, Haroon
Chang, Tara I.
Tan, Marilyn
Mahaffey, Kenneth W.
[J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 209 - 215
[5] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
Schroeder, M.
Johansen, P.
Thompson, G.
Willis, M.
Neslusan, C.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
[6] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
Neslusan, C.
Teschemaker, A.
Martin, S.
Willis, M.
Johansen, P.
[J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
[7] The Long-Term Efficacy and Safety of Canagliflozin in Combination with Insulin in Japanese Patients with T2DM
Harashima, Shinichi
Inagaki, Nobuya
Kaku, Kohei
Kondo, Kazuoki
Maruyama, Nobuko
Otsuka, Makiko
Kawaguchi, Yutaka
Watanabe, Yumi
Goda, Maki
Iijima, Hiroaki
[J]. DIABETES, 2017, 66 : A34 - A34
[8] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
Martin, Silas
Neslusan, Cheryl
Vo, Lien
Teschemaker, Anna
Johansen, Pierre
Willis, Michael
[J]. DIABETES, 2014, 63 : A310 - A310
[9] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
Pfeifer, Michael
Townsend, Raymond
Davies, Michael J.
Vijapurkar, Ujjwala
Ren, Jimmy
[J]. DIABETES, 2016, 65 : A303 - A303
[10] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
Seufert, Jochen
Aggarwal, Naresh
Bailey, Robert
Cao, Anjun
Fung, Albert
Pfeifer, Michael
Alba, Maria
Rodbard, Helena W.
[J]. DIABETES, 2016, 65 : A308 - A308

← 1 2 3 4 5 →